The Met tyrosine kinase ± the HGF receptor ± induces cell transformation and metastasis when constitutively activated. Met signaling is mediated by phosphorylation of two carboxy-terminal tyrosines which act as docking sites for a number of SH2-containing molecules. These include Grb2 and p85 which couple the receptor, respectively, with Ras and PI 3-kinase. We previously showed that a Met mutant designed to obtain preferential coupling with Grb2 (Met 2xGrb2 ) is permissive for motility, increases transformation, but ± surprisingly ± is impaired in causing invasion and metastasis. In this work we used Met mutants optimized for binding either p85 alone (Met 2xPI3K ) or p85 and Grb2 (Met P13K/Grb2 ) to evaluate the relative importance of Ras and PI 3-kinase as downstream eectors of Met. Met 2xPI3K was competent in eliciting motility, but not transformation, invasion, or metastasis. Conversely, Met P13K/Grb2 induced motility, transformation, invasion and metastasis as eciently as wild type Met. Furthermore, the expression of constitutively active PI 3-kinase in cells transformed by the Met 2xGrb2 mutant, fully rescued their ability to invade and metastasize. These data point to a central role for PI 3-kinase in Met-mediated invasiveness, and indicate that simultaneous activation of Ras and PI 3-kinase is required to unleash the Met metastatic potential.
The Met tyrosine kinase ± the HGF receptor ± induces cell transformation and metastasis when constitutively activated. Met signaling is mediated by phosphorylation of two carboxy-terminal tyrosines which act as docking sites for a number of SH2-containing molecules. These include Grb2 and p85 which couple the receptor, respectively, with Ras and PI 3-kinase. We previously showed that a Met mutant designed to obtain preferential coupling with Grb2 (Met 2xGrb2 ) is permissive for motility, increases transformation, but ± surprisingly ± is impaired in causing invasion and metastasis. In this work we used Met mutants optimized for binding either p85 alone (Met 2xPI3K ) or p85 and Grb2 (Met P13K/Grb2 ) to evaluate the relative importance of Ras and PI 3-kinase as downstream eectors of Met. Met 2xPI3K was competent in eliciting motility, but not transformation, invasion, or metastasis. Conversely, Met
Introduction
Hepatocyte growth factor (HGF), also known as Scatter Factor (SF), is a mesenchymal cytokine which triggers in target cells a unique biological program leading to invasive cell growth (reviewed in Jeers et al., 1996; Bardelli et al., 1997a) . The latter results from the integration of multiple biological responses to HGF such as cell proliferation, survival, motility, and invasion of extracellular matrices (Weidner et al., 1993; Medico et al., 1996; Bardelli et al., 1996; Fan et al., 1998) . The HGF receptor is a transmembrane tyrosine kinase encoded by the c-MET proto-oncogene (Bottaro et al., 1991; Naldini et al., 1991) . c-MET is overexpressed and ampli®ed in a number of human tumors (reviewed in Bardelli et al., 1997a) . Recently, a direct genetic link between c-MET and human cancer was established by the identi®cation of activating mutations in the c-MET gene in hereditary papillary renal carcinomas (Schmidt et al., 1997; Fischer et al., 1998; Zhuang et al., 1998) . c-MET was originally identi®ed as the cellular counterpart of a transforming gene, TPR ± MET, resulting from a chromosomal rearrangement (Cooper et al., 1984; Park et al., 1986) . In Tpr ± Met, the extracellular domain of Met is replaced by Tpr sequences, which provide two strong dimerization motifs (Rodrigues and Park, 1993) . Dimerization causes constitutive activation of the Met kinase, which acquires transforming and metastatic properties (Park et al., 1986; Giordano et al., 1997) . Met signaling and Tpr ± Met mediated transformation are based on the activation of multiple pathways triggered by phosphorylation of two carboxy-terminal tyrosines (Y 1349 VHVNATY 1356 VNV, Ponzetto et al., 1993 Ponzetto et al., , 1994 Fixman et al., 1995) . These tyrosine residues are part of a consensus sequence (YVH/NV) which mediates coupling of the receptor with several eectors, including the Grb2/SoS complex (Ponzetto et al., 1994; Fixman et al., 1995) , the p85 regulatory subunit of PI-3-kinase (Ponzetto et al., 1993) , Stat-3 (Boccaccio et al., 1998) , and the multiadaptor protein Gab1 (Weidner et al., 1996; Bardelli et al., 1997b; Nguyen et al., 1997) . Grb2, in particular, requires an Asn in the +2 position for binding, and is thus linked to the receptor via the Y 1356 VNV motif Maina et al., 1996; Fixman et al., 1997) .
In previous work we mutagenized the residues in position +2 of the multifunctional tyrosines ) direct binding with Grb2 . The Met Grb27 mutation severely impaired the transforming activity of Tpr ± Met thus showing that a direct link with the Ras pathway is required for Met-mediated transformation. Conversely, the introduction of a second Grb2 binding site (Met 2xGrb2 ) enhanced transformation but, surprisingly, impaired metastasis (Giordano et al., 1997) . These results suggest that the oncogenic form of the Met receptor may require direct coupling with additional downstream eector(s) besides Grb2, to be fully metastatic. Such eector(s) could be displaced by the insertion of a second high anity binding site for Grb2. As a possible candidate we considered PI 3-kinase, which binds Y 1349 and Y 1356 at low anity (Ponzetto et al., 1993) . PI 3-kinase is a major mediator of HGF-mediated motility (Royal and Park, 1995; Kwaja et al., 1998) , invasion (Keely et al., 1997; Shaw et al., 1997) , and prevention from apoptosis (Kauman-Zeh et al., 1997) , all events relevant to the metastatic process.
In this work, the role of PI 3-kinase in Met-mediated cell motility, transformation, and metastasis was evaluated in two ways: (i) we tested the response of cells expressing Met mutants in which, to preferentially activate PI 3-kinase, either one or both docking sites were converted into the optimal motifs for p85; (ii) we evaluated the eect of introducing a constitutively active catalytic subunit of PI 3-kinase in cells transformed by the poorly metastatic Met 2xGrb2 mutant. The results of these studies show that concomitant activation of Ras and PI 3-kinase is required to sustain the metastatic phenotype of Met-transformed cells, and suggest a central role for PI 3-kinase in the transition of tumor cells to the invasive phenotype.
Results

Construction of Tpr ± Met signaling mutants
Signaling mutants of Tpr ± Met (the oncogenic form of the Met receptor) were generated by site-directed mutagenesis (Table 1) . To preferentially activate PI 3-kinase, two optimal consensus sequences reproducing the p85 binding sites of the PDGF receptor (Fantl et al., 1992; Songyang et al., 1993) were introduced downstream to the tyrosine residues responsible for signal transduction (YVHVNATYVNV?YMPMNA-TYM-DM: Tpr ± Met 2xPI3K ). To enhance binding with PI 3-kinase without uncoupling Grb2, only the ®rst of the two sites was converted into an optimal p85 binding motif: (YVHVNATYVNV?YMPMNATYVNV:
). Also included in the experiments were three previously described mutants designed to speci®cally uncouple Grb2 (YVHVNATYVNV?YVHVNATYVHV: Tpr ± Met .
Tpr ± Met mutants carrying optimized consensus sequences bind and activate Grb2 or PI 3-kinase with increased eciency
We veri®ed that the new consensus sequences did not interfere with the activity of the Met kinase and with phosphorylation of the tyrosine residues using lysates of COS-1 cells expressing the Tpr ± Met mutants for immunoprecipitation and kinase assay. Figure 1a shows the result of an autokinase assay on the various mutants. In this assay the intensity of the Tpr ± Met band re¯ects the level of phosphate incorporation at the major phosphorylation site, Y 1235 , located in the catalytic domain (Ferracini et al., 1991) . The level of auto-kinase activity of all mutants is comparable to wild type, as indicated by the fact that the labeled bands are all of similar intensity (the amounts of Tpr ± Met protein was comparable in all samples, as assessed by Western blot, data not shown). Dierences in phosphorylation of the carboxyterminal tail aect the mobility in SDS ± PAGE of the Tpr ± Met band (Ponzetto et al., 1994) . All the Tpr ± Met mutants appear to be phosphorylated on both tyrosines, as shown by the fact that their migration rate is equivalent to that of Tpr ± Met Wt . The only exception is Tpr ± Met Double , which, given the lack of the two carboxyterminal tyrosines, has a higher migration rate.
Transfected COS-1 cells were also used to assess the relative ability of the Tpr ± Met signaling mutants to bind Grb2 or PI 3-kinase. For Grb2, lysates of COS-1 cells expressing the Tpr ± Met mutants were incubated with GST-Grb2 fusion protein immobilized on Glutathione-Sepharose beads, and bound Tpr ± Met was visualized by autokinase assay. Figure 1b shows that Grb2 binds a higher amount of Tpr ± Met 2xGrb2 compared to Tpr ± Met Wt and to Tpr ± Met
. The Tpr ± Met 2xPI3K mutant, Tpr ± Met
Grb27
, as well as Tpr ± Met Double do not associate Grb2. In agreement with these associations data we have shown that Tpr ± Met 2xGrb2 elicits an increased response with respect to Tpr ± Met
Wt from a Ras-responsive promoter, while the ability of Tpr ± Met 2xPI3K and of Tpr ± Met Grb27 to elicit a Ras-mediated response is impaired (Besser et al., 1997) . For PI 3-kinase, lysates of COS-1 cells transfected with the various Tpr ± Met mutants were immunoprecipitated with anti-Met antibodies and blotted with antibodies speci®c for p85. Figure 1c shows that the mutants with optimal p85 binding site(s) (Tpr ± Met 2xPI3K and Tpr ± Met PI3K/Grb2 ) co-precipitate with an amount of p85 strikingly higher compared to wild type, which is undetectable at this level of exposure. Accordingly, the PI 3-kinase activity associated with Tpr ± Met 2xPI3K or Tpr ± Met PI3K/Grb2 is higher in lysates of cells expressing these mutants, compared to that found in cells expressing Tpr ± Met Wt (Graziani et al., 1991) or Tpr ± Met 2xGrb2 ( Figure 1d ). The presence of one or two optimal p85 binding site(s) Tpr ± Met
, Tpr ± Met 2xPI3K ) does not seem to aect the amount of coimmunoprecipitated p85 or PI 3-kinase activity. This may indicate that in COS cells the level of overexpressed Tpr ± Met protein exceeds the amount of p85-p110 available for binding.
Enhanced coupling of Met to PI 3-kinase elicits motility in epithelial cells
The eects of the signaling mutations on Met-mediated motility were tested in MDCK cells, an epithelial cell line which grows in culture in tight islands and responds to HGF by`scattering' (Stoker et al., 1987) . MDCK cells were co-transfected with the dierent Tpr ± Met constructs and the plasmid psV2neo. G418 Table 1 Tpr ± Met signaling mutants designed to preferentially bind Grb2 or PI 3-kinase
Signaling mutants of the oncogenic form of the Met receptor (Tpr ± Met) were generated by site-directed mutagenesis. The consensus sequences for the SH2 domains of Grb2 and p85 (the regulatory subunit of PI 3-kinase) were designed according to Songyang et al. (1993) . Mutagenized residues are underlined resistant clones were picked and expanded. Expression of Tpr ± Met was determined by either immunoprecipitation and kinase assay, or by Western blot. Clones expressing each of the Tpr ± Met constructs, with the exception of Tpr ± Met Double , had a constitutively motile ®broblast-like phenotype ( Figure 2a ). The clones shown in Figure 2a expressed comparable amounts of Tpr ± Met proteins (Figure 2b) . Thus, preferential coupling with Grb2 or PI 3-kinase is sucient to elicit the Met-mediated motility response.
Preferential coupling to Grb2 on PI 3-kinase has opposite eects on Tpr ± Met-mediated transformation
The transforming potential of the Tpr ± Met 2xPI3K and Tpr ± Met PI3K/Grb2 mutants was evaluated in a focus forming assay, using Rat Fisher ®broblasts. We have previously shown that the mutation abrogating the link with Grb2 (Tpr ± Met Grb27 ) severely impairs transformation, and that duplication of the Grb2 binding site (Tpr ± Met 2xGrb2 ) enhances transformation . Figure 3 shows that preferential coupling of Tpr ± Met with PI 3-kinase (Tpr ± Met 2xPI3K ) drastically lowers the numbers of foci compared to the wild type control, indicating that activation of PI 3-kinase is not sucient for ecient transformation. On the other hand, the Tpr ± Met PI3K/Grb2 mutant, modi®ed to preferentially activate PI 3-kinase together with Ras, is fully competent in mediating transformation ( Figure  3 ). These results indicate that while the requirement for motility can be ful®led by either one of the two pathways, the Met-mediated proliferative signal requires a threshold of Ras activation and cannot be sustained by PI 3-kinase alone. Figure 1 Kinase activity and association of Tpr ± Met signaling mutants with Grb2 and PI 3-kinase. (a) Wild type and mutant Tpr ± Met proteins were immuno-precipitated from COS-1 cells transfected with the corresponding constructs, using antibodies speci®c for human Met and subjected to in vitro kinase assay with [g-32 P]ATP. Labeled proteins were separated on 8% SDS ± PAGE. The gel was dried and exposed for autoradiography. (b) Grb2 fusion protein (approximately 500 ng/point) was immobilized on Glutathione-Sepharose beads and incubated with lysates of COS-1 cells containing comparable amounts of Tpr ± Met mutants. Complexes were washed and the amount of Tpr ± Met bound to Grb2 was visualized by in vitro kinase assay with [g-32 P]ATP. Labeled proteins were separated on 8% SDS ± PAGE. The gel was dried and exposed for autoradiography. (c) Tpr ± Met mutants were immunoprecipitated with anti-Met antibodies from lysates of transfected COS-1 cells. Immunoprecipitates were separated on 8% SDS ± PAGE. Associated p85 was visualized by Western blotting with anti-p85 antibodies. Exposure was optimized to show the amount of p85 associated to the Tpr ± Met 2xPI3K and Tpr ± Met PI3K/Grb2 mutants. Upon longer exposure a faint p85 band can also be detected in the Tpr ± Met Wt lane, as previously shown (Graziani et al., 1991) . (d) Tpr ± Met mutants were immunoprecipitated with anti-Met antibodies from lysates of transfected COS-1 cells and the amount of Tpr ± Met associated PI 3-kinase activity was determined by PI 3-kinase assay. The position of the phosphatidylinositol-3-phosphate (PIP) product of the PI 3-kinase reaction is indicated Preferential coupling to Grb2 or PI 3-kinase impairs the Tpr ± Met metastatic potential Fibroblasts transformed by Tpr ± Met signaling mutants were tested in an experimental metastasis assay. Pools of cells deriving from foci of transformation were injected into the tail vein of nude mice. All the animals injected with cells transformed by Tpr ± Met Wt died within a short latency time (2 weeks), with massive metastatic colonization of the lungs. Cells transformed by either Tpr ± Met 2xGrb2 or Tpr ± Met 2xPI3K were severely impaired in their metastatic potential (Figure 3 ). This indicates that preferential coupling of Tpr ± Met with either Ras or PI 3-kinase interferes with its ability to induce metastasis. Interestingly, the Tpr ± Met mutant capable of activating both Ras and PI 3-kinase (Tpr ± Met PI3K/Grb2 ) was transforming and metastatic. These data suggest that, while coupling with Grb2 is required and sucient for Tpr ± Met-mediated transformation, to induce metastasis the MET oncogene may need to concomitantly activate PI 3-kinase.
Tpr ± Met mediated metastasis requires concomitant activation of Grb2 and PI 3-kinase-mediated pathways and correlates with invasiveness
To establish whether activation of PI 3-kinase could rescue to a fully metastatic phenotype cells transformed by Tpr ± Met 2xGrb2 , we used a constitutively activated variant of the PI 3-kinase catalytic subunit (p110*). p110* is activated via addition of a carboxy-terminal farnesylation signal which relocates the enzyme to the plasma membrane (Khwaja et al., 1997) . Cells transformed by the poorly metastatic Tpr ± Met 2xGrb2 and Tpr ± Met Grb27 mutants were co-transfected with a plasmid encoding p110* and psV2neo. G418-resistant clones were pooled and assayed for p110* expression by Western blot. Pools of cells expressing comparable amounts of p110* (Figure 4a ) were tested in an experimental metastasis assay. Expression of constitutively active PI 3-kinase conferred to Tpr ± Met 2xGrb2 transformed cells (high Ras signal, Besser et al., 1997) a strongly metastatic phenotype, which had no eect on cells transformed by Tpr ± Met Grb27 (low Ras signal; Besser et al., 1997) (Figure 4b ). These results indicate that concomitant activation of Ras and PI 3-kinase unmasks the metastatic potential of the MET oncogene. PI 3-kinase has been shown to play a role in invasion (Shaw et al., 1997) . We therefore evaluated whether there was a correlation between the metastatic potential of Tpr ± Met transformed cells and the acquisition of the ability to cross a barrier of extracellular matrix. Cells expressing Tpr ± Met Wt , Tpr ± Met
, Tpr ± Met Grb27/p110* or Tpr ± Met 2xGrb2/p110* were tested in an invasion assay using Matrigel-coated Transwells. Metastatic cells showed increased invasiveness with respect to non-metastatic controls ( Figure  4c ). 
Discussion
Acquisition of a metastatic phenotype by cancer cells is considered a key step in tumor progression. This process has been shown to correlate with alteration of a number of biological properties among which are cell growth, motility, secretion of proteases, and invasion of extra-cellular matrices (reviewed in Sporn, 1997) . The Met ligand, HGF/SF, has been shown to in¯uence all of these parameters in target cells (reviewed in Jeers et al., 1996; Bardelli et al., 1997a) . Accordingly, the constitutively active oncogenic counterpart of the Met receptor (Tpr ± Met) transforms ®broblasts at high eciency, and renders them highly metastatic (Park et al., 1986; Giordano et al., 1997) . Met signaling and transformation depend on ligand-induced phosphorylation of two carboxy-terminal docking sites of mixed speci®city (Y 1349 /VHVNATY 1356 /VNV, Ponzetto et al., 1994; Fixman et al., 1995; Maina et al., 1996) . These phosphotyrosines are responsible for recruiting a number of SH2-containing eectors, including p85 (the regulatory subunit of PI 3-kinase) and the Grb2 adaptor (Ponzetto et al., 1994) . While p85 binds at low anity to either site, Grb2 binds at high anity to Y 1356 VNV, and links the receptor directly to the Ras pathway via the Grb2/SoS complex (Ponzetto et al., 1993 (Ponzetto et al., , 1994 Fixman et al., 1997) . In previous work we duplicated the endogenous Grb2 binding site ( Y 1349 VHVNATY 1356 VNV ? Y 1349 VNVNATY 1356 VNV ) to enhance Tpr ± Met-mediated Ras signaling. This mutant caused an increased response from a Rasresponsive promoter (Besser et al., 1997) and was more transforming than wild type . However, cells transformed by this mutant were impaired in their ability to invade extra-cellular matrices in vitro and to induce metastasis in nude mice (Giordano et al., 1997) .
In this paper, to investigate the role of PI 3-kinase in Met-mediated events (motility, transformation and metastasis), we used the same approach of`optimizing' the receptor docking sites to bind a speci®c eector. The new mutants were engineered to preferentially activate PI 3-kinase either alone (Tpr ± Met 2xPI3K ), or in combination with Ras (Tpr ± Met
PI3K/Grb2
). This was done by modifying the three residues downstream to one or both of the multifunctional tyrosines into optimal p85 consensus sequences (YMPM, YMDM: Songyang et al., 1993) . It should be noted, however, that according to Larose et al. (1995) the p85 consensus pYMXM is also compatible with PLC-g binding, unless a Ser residue is inserted in position +4. In our mutants the residues in position +4 are Asn and Lys. Thus the two new mutants, in addition to having acquired a much stronger PI 3-kinase binding site than Tpr ± Met Wt , might retain the ability of coupling with PLC-g. The mutations were inserted in the constitutive active oncogenic form of the receptor Tpr ± Met, and the constructs were transfected in epithelial cells (MDCK) or in rat Fisher ®broblasts to study the eect of the mutations, respectively, on motility and transformation/metastasis.
All mutants imparted a constitutively`scattered' phenotype to MDCK cells. In particular, the eect of Tpr ± Met Wt invasive potential and represent the number of cells that had dived into the lower compartment of the Transwell. Values are the averages of three independent experiments performed in duplicate PI 3-kinase is sucient to induce scattering. HGF/SFinduced Ras and PI 3-kinase activation have been shown to be both necessary for the scattering response, using dominant negative constructs or speci®c inhibitors (Hartmann et al., 1994; Derman et al., 1996) . Recently, expression of constitutively activated PI 3-kinase has been shown to be sucient to cause scattering in MDCK cells, provided that a basal level of MAP kinase activity is present (Khwaja et al., 1998) . We have previously shown that the Tpr ± Met 2xPI3K mutant elicits from a Ras responsive promoter a response which is 25% of wild type (Besser et al., 1997) . This threshold of Ras signaling combined with Met-mediated PI 3-kinase activation is thus sucient to confer motility to epithelial cells. Conversely, the fact that the Tpr ± Met 2xPI3K mutant was inecient in a focus forming assay indicates that a higher threshold of Met-mediated Ras activation is required for transformation.
When cells transformed by the Tpr ± Met 2xPI3K mutant were tested in an experimental metastasis assay, they were impaired in causing lung metastastes in nude mice, behaving like those transformed by the mutant optimized for Grb2 binding (Tpr ± Met 2xGrb2 : Y 1349 VNVNATY 1356 VNV). Thus, by tilting the balance of downstream signaling toward preferential activation of one of the two pathways we interfere with the ability Tpr ± Met to induce a metastatic phenotype.
Furthermore, a fully metastatic Tpr ± Met mutant was obtained by mutating the degenerate Y 1349 VHV site into an optimal motif for PI 3-kinase, while leaving unmodi®ed the endogenous Grb2 binding site (Tpr ± Met
: Y 1349 MPMNATY 1356 VNV). This suggested that it is sucient to activate PI 3-kinase concomitantly with Grb2-dependent pathways to elicit the invasive/metastatic response. To verify this hypothesis directly, cells transformed by the poorly metastatic Tpr ± Met 2xGrb2 mutant were transfected with a constitutively active form of the catalytic subunit of PI 3-kinase (p110*; Khwaja et al., 1997) . Expression of p110* fully rescued the metastatic ability of these cells, con®rming that both pathways are required for metastasis.
The results of our studies with the Grb2-or PI 3-kinase-directed Met signaling mutants highlight the synergistic eect the combined two pathways have in mediating the complex series of events leading to the acquisition of a fully metastatic phenotype. It seems likely that the picture of Ras and PI 3-kinase cooperation emerging from the use of these mutants could, by and large, re¯ect how the wild type version of Met naturally implements the biological eects of HGF/SF. While there is clear evidence that PI 3-kinase is a Met downstream target (Graziani et al., 1991; Royal and Park, 1995; Derman et al., 1996; Khwaja et al., 1998 ) the process whereby PI 3-kinase is activated by wild type Met is not completely understood. The two carboxy-terminal multifunctional tyrosines in the receptor are relatively low anity binding sites for p85 (Ponzetto et al., 1993; Songyang et al., 1993) . Conversely, three`optimal' p85 binding motifs are present in the multiadaptor GAB-1, a Met substrate which binds the receptor via Grb2 (Holgado-Madruga et al., 1996; Weidner et al., 1996; Bardelli et al., 1997b; Fixman et al., 1997) . Thus, PI 3-kinase activation in vivo is likely to occur mainly indirectly, through Grb2-mediated GAB-1 phosphorylation. If this is the case, insertion of a second Grb2 binding site should not interfere with PI 3-kinase activation. However, the biological defect of the Tpr ± Met 2xGrb2 mutant and its rescue by the activated form of PI 3-kinase, indicate that the mutation somehow upsets the balance between the two pathways. In this respect, it is interesting to note the changes that occurred in the multifunctional docking site of c-Sea (another member of the Met family of receptors, Hu et al., 1993) , after the sequence was acquired by the avian erythroblastosis virus (Smith et al., 1989) . In c-Sea the two tyrosines responsible for signal transduction are both Grb2 binding site (YVNLAVTYVNL). Accordingly, the corresponding Tpr ± Sea is transforming, but not highly metastatic (Giordano et al., 1997) . Interestingly, v-Sea acquired a mutation imparting the ability to bind also PI 3-kinase to the ®rst Grb2 binding site (YLNMAVTYVNL). It is highly suggestive that the oncogenic counterpart of the c-Sea receptor should be a variant which has acquired the potential for concomitant activation of both pathways.
Regardless of the precise mechanisms through which Met achieves PI 3-kinase activation, this work establishes a critical role for this pathway in the acquisition of the metastatic properties of Mettransformed cells.
Materials and methods
Reagents, cells and antibodies
All reagents, unless speci®ed, were purchased from Sigma Chemical Co. Protein A covalently coupled to Sepharose was purchased from Pharmacia LKB Biotechnology Inc. Radioactive isotopes were purchased from Amersham Corp. MDCK cells, COS-1 cells and Fisher rat fibroblasts were purchased from ATCC (American Type Culture Collection). Cells were cultured in DMEM medium supplemented with 10% FCS (Flow Laboratories, Inc.) in a 5% CO 2 -water-saturated atmosphere. The GST-Grb2 fusion protein has been previously described . Antisera and monoclonal anti-Met antibodies were kindly provided by Dr M Prat. Monoclonal anti-p85 and anti-Myc antibodies were from Upstate Biotechnology (UBI) and Sigma, respectively.
Mutagenesis, cloning and expression of cDNA constructs
To generate the Met carboxy-terminal mutations an in vitro oligonucleotide site-directed mutagenesis system (Promega) was used as previously reported (Ponzetto et al., 1993) . TPR ± MET cDNAs carrying the indicated mutations were reconstructed in the pMT2 vector, for transient expression in COS-1 cells. The plasmid (pSG5 p110CAAX) encoding the activated form of PI 3-kinase (p110*), obtained by addition of the C-terminal farnesylation signal from HaRas, has been previously described (Khwaja et al., 1997) .
Plasmids were transfected in COS-1 and MDCK cells by the lipofection procedure (GIBCO ± BRL). For selection of stable transfectants, cells (MDCK and Fisher rat ®broblasts) were cotransfected with the appropriate plasmid and with pSV2neo. Cells were maintained in DMEM containing 10% calf serum and 750 mg/ml G418.
Immunoprecipitation and Western blotting
Cells were lysed with EB buer (100 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA, 10% glycerol, 1% Triton X-100, 1 mM Sodium orthovanadate) and a cocktail of protease inhibitors (pepstatin, leupeptin, aprotinin and PMSF). Immunoprecipitation (with the indicated antibodies) was performed in EB buer. After SDS ± PAGE, proteins were transferred to Hybond-ECL membranes (Amersham). Filters were probed with the appropriate antibodies and speci®c binding was detected by the Enhanced Chemiluminescence System (ECL, Amersham).
In vitro kinase assay Tpr ± Met proteins were immunoprecipitated with anti-Met antibodies coupled to Protein A-Sepharose. Immunocomplexes were washed with EB buer and incubated with kinase buer (KB: 50 mM HEPES pH 7.5, 150 mM NaCl, 12.5 mM MgCl 2 ) in the presence of [g-32 P]ATP. The reaction was carried out at 258C for 15 min, and stopped by adding concentrated boiling Laemmli buer. The eluted proteins were subjected to SDS ± PAGE followed by autoradiography.
Focus forming assay
Transfection of the TPR ± MET constructs in Fisher Rat ®broblasts was carried out using the DNA-calcium phosphate coprecipitation method (CellPhect Transfection Kit, Pharmacia). Cells (one 10 cm dish at 60% con¯uence) were transfected with 10 mg of DNA. After transfection cells were split 1 : 10 and kept in DMEM medium with 5% FCS. Formation of foci was detected in 2 ± 3 weeks.
Experimental metastasis assays
Experimental metastasis assays were carried out in nude mice. Mice (6/each group) were injected in the tail vein with 10 6 transformed cells (pools of 10 foci). The experiment was repeated three times. Two weeks was chosen as a reference point to evaluate lethality (due to lung metastases) since in this series of experiments animals injected with cells transformed by Tpr ± Met Wt were invariably all dead by this time. All animals injected with cells transformed by Tpr ± Met signaling mutants would eventually die at later times. The presence of lung metastasis was evaluated at necropsy and con®rmed by histopathological examination of the lungs.
Transwell invasion assays
Invasion assays were performed using Transwells (6.5 mm, Costar, Cambridge, MA, USA). The polycarbonate membranes (8-mm pore size) on the bottom of the upper compartment of the Transwells were coated with 1.2 mg/ml Matrigel (Collaborative Research, Waltham, MA, USA). Cells (10 5 in 200 ml of DMEM 5% FCS) were placed in the upper compartment. One ml of DMEM 5% FCS was added to the lower compartment. The Transwell containing plates were incubated at 378C in a 5% CO 2 atmosphere saturated with H 2 O for 48 h. At the end of incubation, cells that had dived to the lower compartment of the Transwell were ®xed with 11% glutharaldehyde for 15 min at room temperature, washed three times with distilled water, and stained with 0.1% crystal violet-20% methanol for 20 min at room temperature for counting.
